Ireland
--:--IST
Latest
Priya Life Science Medicines register
Registers› Irish medicines ›Equasym XL 20 mg modified-release capsules, hard
Medicines register · Ireland

Equasym XL 20 mg modified-release capsules, hard

Authorisation PA23211/001/002 · Takeda Pharmaceuticals International AG Ireland Branch

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. Published 08 Oct 2026
Licence holder
Takeda Pharmaceuticals International AG Ireland Branch (all products →)
Active substance
Methylphenidate hydrochloride
Clinical trials
12 clinical trials →
Dosage form
Modified-release capsule, hard
Route of administration
Not Currently Available
ATC codes
N06BA, N06BA04
First authorised
28/07/2006
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Methylphenidate hydrochloride: supply and approvals

32 authorised products on the HPRA list contain Methylphenidate hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
ADHD medicines: Shortage ongoing, first published 18 Dec 2023
US shortage (FDA)
Methylphenidate Hydrochloride Tablet, Extended Release: in shortage, updated 1 Oct 2026
Methylphenidate Film, Extended Release: in shortage, updated 2 Sep 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 8 Oct 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 9 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.